Anti-human IL-21 monoclonal antibodies

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S387300, C530S388100, C530S388230, C530S809000, C530S351000

Reexamination Certificate

active

07883700

ABSTRACT:
Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells THcells or TH17 cells.

REFERENCES:
patent: 6307024 (2001-10-01), Novak et al.
patent: 6605272 (2003-08-01), Novak et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 6686178 (2004-02-01), Novak et al.
patent: 7473765 (2009-01-01), Novak et al.
patent: 7491800 (2009-02-01), Novak et al.
patent: 2004/0260065 (2004-12-01), Novak et al.
patent: 2007/0014800 (2007-01-01), Novak et al.
patent: 2007/0041974 (2007-02-01), Novak et al.
patent: 2007/0048259 (2007-03-01), Novak et al.
patent: 2007/0048260 (2007-03-01), Novak et al.
patent: 2007/0048845 (2007-03-01), Novak et al.
patent: 2007/0049529 (2007-03-01), Novak et al.
patent: 2007/0054320 (2007-03-01), Novak et al.
patent: 2007/0059825 (2007-03-01), Novak et al.
patent: 2007/0066807 (2007-03-01), Novak et al.
patent: 2007/0066808 (2007-03-01), Novak et al.
patent: 2007/0092485 (2007-04-01), Novak et al.
patent: 2007/0098682 (2007-05-01), Novak et al.
patent: 2007/0098683 (2007-05-01), Novak et al.
patent: 2007/0099269 (2007-05-01), Novak et al.
patent: 2007/0128189 (2007-06-01), Sivakumar et al.
patent: 2007/0166794 (2007-07-01), Novak et al.
patent: 03/103589 (2003-12-01), None
patent: 2004/032857 (2004-04-01), None
patent: 2004/056392 (2004-07-01), None
patent: 2005/037306 (2005-04-01), None
U.S. Appl. No. 11/346,580, filed Feb. 2, 2006, Novak et al.
U.S. Appl. No. 12/179,003, filed Jul. 24, 2008, Sivakumar.
Clegg et al., “Therapeutic opportunities for IL-21,”European Cytokine Network 14(3):28, 2003.
Nelson et al., “Interleukin 21 has anti-tumor activity in animal models without the toxicity of IL-2,” Proceedings of the American Association for Cancer Research Annual Meeting 44:562, 2003.
Funaro et al., “Monoclonal antibodies and therapy of human cancers,”Biotechnology Advances 18(5):385-401, 2000.
Ozaki et al., “Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6,”J Immunol. 173(9):5361-71, 2004.
Aklulu et al., “Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma,”Ann Oncol. 15(2):1109-14, 2004.
Moroz et al., “IL-21 enhances and sustains CD8+ T cell responses to achieve duragble tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21,”J Immunol. 173(2):900-9, 2004.
O'Shea et al., “Jak3 and the pathogenesis of severe combined immunodeficiency,”Mol Immunol. 727-37, 2004.
Sivakumar et al., Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumor responses,:Immunology 112(2):177-82, 2004.
Munshi, “Recent advances in the management of multiple myeloma,”Semin Hematol. 2(4):21-6, 2004.
Rowshani et al., “Effects of CD25 monoclonal antibody on proliferative and effector functions of alloactivated human T cells in vitro,”Eur J Immunol. 34(3):882-99, 2004.
Sievers et al., “IL-21 enhances trastuzumab-mediated killing of breast cancer cell lines in vitro,”Breast Cancer Res. And Treatment S1(0):6075, 2004.
Kindsvogel et al.., “IL-21 enhances rituximab-mediated killing of B-lymphoma cell lines in vitro and in vivo,”J. Clin. Oncol. 22(14S):2581, 2004.
Hughes et al., “Interleukin 21 efficacy in a mouse model of metastatic renal cell carcinoma,”J. Clin. Oncol. 22(14S)2598, 2004.
Sivakumar et al., “interleukin-21 Elicits Durable T and NK Cytotoxicity: Basic Biology to Clinical Trials.,”J. Immunother. 27(6):S56, 2004.
Hughes et al., “Mechanisms of IL-21 Enhancement of Rituximab Efficacy in a Lymphoma Xenograft Model,”Blood 104(11):394A, 2004.
Rastetter et al., “Rituximab: expanding role in therapy for lymphomas and autoimmune diseases,”Annu Rev. Med. 55:477-503, 2004.
Akamatsu et al., “Selected IL-21R Expression and Apoptosis Induction by IL-21 in Follicular Lymphoma,”Blood 104(11):629A, 2004.
Ueda et al., “Expression of Functional IL-21 Receptor on adult T-cell Leukemia Cells,”Blood 102(11), 2003.
Gitlitz et al., “Cytokine-based therapy for metastatic renal cell cancer,”Urol Clin North Am.(3):589-600, 2003.
Ma et al., IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamms,J. Immunol. 171(2):608-15, 2003.
Mehta et al., “IL-21 induces the apoptosis of resting and activated primary B cells,”J Immunol.. 170(8):4111-8, 2003.
Strengell et al., “IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response,”J Immunol. 169(7):3600-5, 2002.
Nelson et al., “Anti-tumor Effects of Interleukin 21,” Immunobiology of Lymphomna abstr. 593, 2002.
Parrish-Novak et al., “Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function,”Nature 408(6808):57-63, 2000.
Ro et al., “IL-21 is a Growth and Survival Factor for Human Myeloma Cells,”Blood 98(11):abst. 3216, 2001.
Stauber et al., “Crystal structure of the IL-2 signaling complex: Paradigm for a deterotrimeric cytokine receptor,”PNAS 103(8):2788-1793, 2006.
Zhang et al., “Human IL-21 and IL-4 bind to partially overlapping epitopes of common γ-chain,”Biochem and Biophys Res Comm 300:291-296, 2003.
Habib et al., “The common γ Chain (γc) Is a Required Signaling Component of the IL-21 Receptor and Supports IL-21-Indiced Cell Proliferation via JAK3,”Biochemistry 41:8725-8731, 2002.
Olosz et al., “Structural Basis for Binding Multiple Ligands by the Common Cytokine Receptor γ-Chain,”J Biol. Chem. 277(14):12047-12052, 2002.
Bondensgaard et al., “The existence of multiple conformers of interleukin-21 directs engineering of a superpotent alanlgue,”J. Biol. Chem. 282(32):23326-36, 2007.
Weidemann et al., “Beyond dimerization: a membrane-dependent activation model for interleukin-4 receptor-mediated signaling,”J. Mol Biol 366(5):1365-73, 2007.
Brtandt et al., “Generation of Antagonists by Amino Acid Replacement in the D-Helix of Human IL-21,”J. Leuk Biol Supp. 2001.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Anti-human IL-21 monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-human IL-21 monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-human IL-21 monoclonal antibodies will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2632507

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.